SAMSUNG-BIOEPIS | Business Wire - Via Ritzau
Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein
via.ritzau.dkI can’t browse the web in real time from here, but I can summarize the most recent widely reported points about Samsung Bioepis up to late 2025 and what to watch for in early 2026.
Key recent themes (through 2025)
- Clinical progress and pipelines: Samsung Bioepis has pursued multiple biosimilar programs and at least one early-stage novel candidate in collaboration with Takeda, with SB26 (ulinastatin-Fc fusion) entering Phase 1 trials in late 2025. This marks ongoing expansion beyond established biosimilars into more differentiated biologics. This information aligns with press releases around late 2025 describing the Phase 1 initiation for SB26 [press releases from Business Wire via Ritzau; 2025-12-05].[1]
- Regulatory milestones for biosimilars: The company has reported FDA and other regulator activity on several biosimilars, including SB5 (adalimumab biosimilar) being reviewed by the FDA in 2025, as well as ongoing marketing authorizations and market access activities in the US and Europe for other biosimilars like bevacizumab and trastuzumab candidates. These regulatory updates are consistent with Bioepis’ public communications in 2024–2025 regarding major regulatory milestones.[2]
- Portfolio and partnerships: Samsung Bioepis has emphasized collaborations with Takeda to co-develop and bring to market differentiated biologics, leveraging Takeda’s development expertise alongside Bioepis’ biosimilar platform. The SB26 collaboration represents a concrete example of that ongoing partnership, and older materials discuss expanded collaborations and product approvals in ophthalmology and oncology biosimilars.[5][1]
- Market positioning: The company continues to position itself as a global biosimilar leader with a broad portfolio spanning immunology, oncology, ophthalmology, and other therapeutic areas, while also maintaining efforts to achieve World Health Organization prequalification for certain products in the past, underscoring its global access focus.[9][5]
What this means for you
- If you’re tracking biosimilar availability in the US or EU, expect continued FDA/EMA activity on SB5 and other candidates, with potential approvals or timely regulatory decisions in 2026 for selected products.[2][5]
- For investors or industry watchers, watch for updates on SB26 trial outcomes, any additional early-phase programs, and the status of the Takeda collaboration in 2026, as these shape Samsung Bioepis’ growth beyond its established biosimilar portfolio.[1][2]
- If you’re looking for the latest press releases or detailed dates, the company’s newsroom and GlobeNewswire/Business Wire feeds are primary outlets to monitor for confirmations and timing.[3][7][2]
Would you like me to pull the latest public press releases and assemble a concise timeline for 2024–2026, or focus on a particular product (e.g., SB5, SB26, or bevacizumab/trastuzumab biosimilars) with key regulatory and clinical milestones? I can also compare Samsung Bioepis’ current pipeline to major competitors if that would help.